Insider Trading History of Cauwenbergh Geert

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Cauwenbergh Geert since 2006. The trader's CIK number is 1285648. At the time of the last reporting, Cauwenbergh Geert was the Chief Executive Offi of Rxi Pharmaceuticals Corp. (stock ticker symbol RXII). Also see all insider trading activities at Rxi Pharmaceuticals Corp.

Note that in the past CAUWENBERGH GEERT also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Rxi Pharmaceuticals Corp (RXII) by Cauwenbergh Geert

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2017 RXII 90,000 $58,077 0 $0 0 $0
2015 RXII 21,000 $21,049 0 $0 0 $0
2014 RXII 34,900 $79,391 0 $0 0 $0
2013 RXII 12,367 $45,098 0 $0 0 $0

Yearly summary of insider trading at Barrier Therapeutics Inc (BTRX) by Cauwenbergh Geert

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2006 BTRX 9,000 $60,198 0 $0 0 $0


Insider trading activities at 2 companies by Cauwenbergh Geert:

1. Rxi Pharmaceuticals Corp (RXII)

2. Barrier Therapeutics Inc (BTRX)

Table 1. Insider trading of Rxi Pharmaceuticals Corp (RXII) by Cauwenbergh Geert

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2017-10-02 RXII Buy 10,000 .45 4,500
2017-08-24 RXII Buy 10,000 .55 5,520
2017-06-22 RXII Buy 10,000 .62 6,250
2017-04-26 RXII Buy 10,000 .65 6,480
2017-03-17 RXII Buy 10,000 .77 7,670
2017-02-17 RXII Buy 10,000 .69 6,929
2017-02-08 RXII Buy 10,000 .69 6,850
2017-01-25 RXII Buy 10,000 .69 6,929
2017-01-19 RXII Buy 10,000 .69 6,949
2015-04-02 RXII Buy 5,000 .72 3,595
2015-02-17 RXII Buy 4,000 1.17 4,680
2015-02-10 RXII Buy 2,000 1.24 2,474
2015-01-20 RXII Buy 10,000 1.03 10,300
2014-12-30 RXII Buy 2,500 1.59 3,970
2014-10-13 RXII Buy 3,000 1.68 5,040
2014-09-19 RXII Buy 4,500 2.20 9,900
2014-09-16 RXII Buy 5,000 2.08 10,390
2014-09-15 RXII Buy 10,000 2.19 21,870
2014-07-15 RXII Buy 1,000 2.50 2,500
2014-07-09 RXII Buy 1,400 2.57 3,598
2014-07-02 RXII Buy 2,000 2.86 5,714
2014-06-25 RXII Buy 500 3.01 1,505
2014-06-19 RXII Buy 2,000 2.98 5,968
2014-06-09 RXII Buy 1,000 3.05 3,050
2014-06-04 RXII Buy 2,000 2.94 5,886
2013-10-30 RXII Buy 200 3.09 618
2013-10-31 RXII Buy 800 3.19 2,552
2013-10-23 RXII Buy 1,000 3.34 3,340
2013-10-18 RXII Buy 400 3.39 1,356
2013-10-22 RXII Buy 300 3.43 1,029
2013-10-14 RXII Buy 100 3.54 354
2013-10-15 RXII Buy 100 3.51 351
2013-10-16 RXII Buy 100 3.53 353
2013-10-09 RXII Buy 1,000 3.15 3,150
2013-10-03 RXII Buy 100 3.51 351
2013-10-04 RXII Buy 200 3.49 698
2013-09-30 RXII Buy 300 3.42 1,026
2013-09-24 RXII Buy 100 3.49 349
2013-09-26 RXII Buy 300 3.50 1,050
2013-09-23 RXII Buy 174 3.49 607
2013-09-20 RXII Buy 326 3.52 1,147
2013-09-18 RXII Buy 200 3.49 698
2013-09-17 RXII Buy 200 3.55 710
2013-09-13 RXII Buy 200 3.58 715
2013-09-11 RXII Buy 150 3.55 532
2013-09-10 RXII Buy 350 3.62 1,265
2013-08-30 RXII Buy 300 3.37 1,009
2013-08-29 RXII Buy 400 3.48 1,390
2013-08-27 RXII Buy 100 3.70 370
2013-08-23 RXII Buy 300 3.72 1,116
2013-08-22 RXII Buy 300 3.62 1,086
2013-08-21 RXII Buy 680 3.80 2,584
2013-08-20 RXII Buy 700 3.78 2,648
2013-08-19 RXII Buy 320 3.73 1,192
2013-08-06 RXII Buy 350 4.05 1,417
2013-08-05 RXII Buy 650 4.01 2,609
2013-07-31 RXII Buy 167 4.02 671
2013-07-31 RXII Buy 500 4.10 2,050
2013-07-29 RXII Buy 500 4.54 2,270
2013-07-26 RXII Buy 500 4.87 2,435

Table 2. Insider trading of Barrier Therapeutics Inc (BTRX) by Cauwenbergh Geert

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2006-08-09 BTRX Buy 2,000 5.43 10,862
2006-05-19 BTRX Buy 5,000 6.17 30,840
2006-03-15 BTRX Buy 2,000 9.25 18,496

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Cauwenbergh Geert (Chief Executive Offi of Rxi Pharmaceuticals Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.